Aussie exec shares FDA experience

Posted 17 June 2025 AM

Getting a drug approved by the FDA can be hard, especially when it's the first of its type but Mesoblast had a particularly bumpy ride.

During the 2025 ARCS Conference, Mesoblast Head of Research and New Product Development, Dr Paul Simmons, shared his experience of getting a new treatment approved by the FDA, with mesenchymal stromal cell (MSC) therapy Ryoncil getting the tick in December to treat steroid-refractory acute graft versus host disease (GVHD) in children.

To see the whole article, please login